MedWatch

Biogen upgrades financial guidance after exceeding expectations in Q2

Halfway through the accounting year, Biogen predicts a higher revenue than previously expected.

Photo: BRIAN SNYDER/REUTERS / X90051

US firm Biogen has upgraded its guidance for the financial year and now predicts a higher revenue than originally expected, Bloomberg News writes based on the company's Q2 report.

The pharmaceutical company now predicts a revenue of between USD 10.65bn and USD 10.85bn, compared to its previous expectation of between USD 10.45bn and USD 10.75bn. The analyst consensus estimate was a USD 10.59bn revenue.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs